Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Amgen Inc.

(AMGN)

Cephalon Inc.

(CEPH)

Chiron Corp.

(CHIR)

CytoTherapeutics Inc.

(CTII)

Regeneron Pharmaceuticals Inc.

(REGN)

Rhone-Poulenc Rorer

SmithBarney analyst Toni Claudio surveyed recent clinical trials of compounds to treat amyotrophic lateral sclerosis. She concluded that RPR's

Rilutek

,

Read the full 383 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE